Pan-RAF:MEK Molecular Glues Take Center Stage | Synapse

⌘+K

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Abstract 2948: A spatial-trapping mechanism of RAF by RAF/MEK glue enables full-dose combination with a pan-RAF inhibitor and drives potent, RAS-mutant tumor-selective MAPK and growth inhibition.Original Research · 2026 · 1 citations
2Spatial modulation of RAF by RAF/MEK glue enables full-dose combination with pan-RAF inhibitor and potent RAS-mutant tumor-selective MAPK and growth inhibitionOriginal Research · 2026
3Data from The Pan-RAF–MEK Nondegrading Molecular Glue NST-628 Is a Potent and Brain-Penetrant Inhibitor of the RAS–MAPK Pathway with Activity across Diverse RAS- and RAF-Driven Cancers2024
4The Pan-RAF–MEK Nondegrading Molecular Glue NST-628 Is a Potent and Brain-Penetrant Inhibitor of the RAS–MAPK Pathway with Activity across Diverse RAS- and RAF-Driven Cancers2024 · 51 citations
5Supplementary Methods from The Pan-RAF–MEK Nondegrading Molecular Glue NST-628 Is a Potent and Brain-Penetrant Inhibitor of the RAS–MAPK Pathway with Activity across Diverse RAS- and RAF-Driven Cancers2024

Supplementary Methods from The Pan-RAF–MEK Nondegrading Molecular Glue NST-628 Is a Potent and Brain-Penetrant Inhibitor of the RAS–MAPK Pathway with Activity across Diverse RAS- and RAF-Driven Cancers2024
Supplementary Methods from The Pan-RAF–MEK Nondegrading Molecular Glue NST-628 Is a Potent and Brain-Penetrant Inhibitor of the RAS–MAPK Pathway with Activity across Diverse RAS- and RAF-Driven Cancers2024
Supplementary Methods from The Pan-RAF–MEK Nondegrading Molecular Glue NST-628 Is a Potent and Brain-Penetrant Inhibitor of the RAS–MAPK Pathway with Activity across Diverse RAS- and RAF-Driven Cancers2024
Neuroendocrine Differentiation Mediates Escape from HER2-Targeted Therapy in Breast CancerCancer Discovery · 2026
Extracellular matrix stiffness controls Transposable Elements through Pin1 to promote immune evasion in breast cancerCancer Discovery · 2026

More from Cancer Discovery

More from University of California, San Diego